Home HOME Acta Virologica 2018 Acta Virologica Vol.62, No.4, p.394-400, 2018

Journal info

Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Aims and Scope
Editorial Info

Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.62, No.4, p.394-400, 2018

Title: Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy
Author: F. Sobhanimonfared, T. Bamdad, Z. A. Sadigh, H. R. Nikoo, H. Choobin

Abstract: Oncolytic virotherapy offers the potential to treat tumors both as a single agent and in combination with conventional therapies such as chemotherapy and immunological therapy. Here, we describe an effective treatment regimen which combines virotherapy with immunotherapy. IFN-α and co-stimulator IL-2 along with tumor cell lysate vaccination with intratumoral administration of oncolytic vesicular stomatitis virus (VSV) resulted in regression of established TC1 papilloma tumor model in C57BL/6 mice. The remarkable results especially in the group receiving tumor vaccination and virotherapy together (TC1-VSV) were obtained. Combination therapy synergistically enhanced CTL activity against tumor cells and reduced tumor size, although significant reduction in tumor size was observed in both groups receiving VSV or tumor vaccine alone. The presented data suggest that the effectiveness of virotherapy is enhanced when combined with immunotherapy by priming specific CD8 T cells against tumor antigens through tumor vaccination and boosting by exposure of antigens upon virus infection.

Keywords: virotherapy; VSV; tumor vaccine; immunotherapy; IFN-α; IL-2
Published online: 23-Nov-2018
Year: 2018, Volume: 62, Issue: 4 Page From: 394, Page To: 400

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.